Skip to main content

Advertisement

Table 2 Associations between vascular risk factors at baseline and progression measured by annual change in CDR-SB

From: Association between vascular comorbidity and progression of Alzheimer’s disease: a two-year observational study in Norwegian memory clinics

  Age and sex-adjusted
  Beta 95% CI p R2
Vascular risk factors (VRFs)
 Hypertension −0.049 (−0.617, 0.519) 0.87 0.04
 Hypercholesterolemia 0.262 (−0.153, 0.676) 0.22 0.05
 Diabetes mellitus 0.128 (−0.592, 0.848) 0.73 0.04
 Overweight (BMI ≥25) − 0.391 (− 0.840, 0.059) 0.09 0.04
 Smoking (current) 0.050 (−0.677, 0.778) 0.89 0.04
  ≥ 2 VRFs 0.121 (−0.370, 0.612) 0.63 0.03
  ≥ 3 VRFs −0.371 (−0.889, 0.147) 0.16 0.04
 Framingham Stroke Risk Profile, women* −0.297 (−2.769, 2.175) 0.81 0.00
 Framingham Stroke Risk Profile, men* 0.930 (−1.638, 3498) 0.47 0.01
 ApoE ε4 carrier 0.384 (−0.069, 0.836) 0.10 0.06
Vascular diseases
 Heart disease 0.196 (−0.380, 0.771) 0.50 0.04
 Atrial fibrillation −0.159 (0.902, 0.583) 0.67 0.04
 Peripheral vascular disease 0.512 (−0.834, 1.858) 0.46 0.04
 Cerebrovascular event (stroke and/or TIA) −0.315 (−0.896, 0.265) 0.29 0.04
MRI findings
 Cortical infarcts (1 = cortical infarcts, 0 = no cortical infarcts) 0.707 (−0.518, 1.932) 0.26 0.04
 Lacunes (1 = ≥1 lacune on MRI, 0 = no lacunes) −0.177 (−0.867, 0.514) 0.61 0.04
 Infarcts (cortical and/or lacunes) 0.038 (−0.611, 0.687) 0.91 0.03
 White matter hyperintensities Fazekas 3 −0.291 (−0.872, 0.290) 0.32 0.04
 White matter hyperintensities Fazekas 2 or 3 −0.207 (−0.776, 0.362) 0.47 0.04
 Infarcts and/or WMH Fazekas 3 −0.079 (−0.625, 0.468) 0.78 0.03
 Infarcts and/or WMH Fazekas 2 or 3 −0.298 (−0.872, 0.277) 0.31 0.04
 MTA (mean of right and left side) 0.036 (−0.262, 0.334) 0.81 0.04
  1. * The Framingham Stroke Risk Profiles were not adjusted for age and sex